Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Top Cited Papers
Open Access
- 2 October 2023
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 29 (11) , 2825-2834
Abstract
Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving a clinical complete response (cCR) could proceed without cystectomy. The co-primary objectives were to assess the cCR rate and the positive predictive value of cCR for a composite outcome: 2-year metastasis-free survival in patients forgoing immediate cystectomy or ATM,RB1,FANCCandERCC2) or increased tumor mutational burden did not improve the positive predictive value of cCR. Exploratory analyses of peripheral blood mass cytometry and soluble protein analytes demonstrated an association between the baseline and on-treatment immune contexture with clinical outcomes. Stringently defined cCR after gemcitabine, cisplatin, plus nivolumab facilitated bladder sparing and warrants further study. ClinicalTrials.gov identifier:NCT03558087.Keywords
Funding Information
- V Foundation for Cancer Research (T2019-011)
- Bristol-Myers Squibb (CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA196521, U24CA224319)
- Foundation for the National Institutes of Health (FNIH)/Partnership for Accelerating Cancer Therapies
This publication has 50 references indexed in Scilit:
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical EvidenceClinical Cancer Research, 2014
- The Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the BladderJournal of Urology, 2014
- Clinical–Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data BaseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder CancerNew England Journal of Medicine, 2012
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06Journal of Clinical Oncology, 2009
- A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219)Journal of Urology, 2009
- Bladder Preservation in Selected Patients with Muscle-Invasive Bladder Cancer by Complete Transurethral Resection of the Bladder Plus Systemic Chemotherapy: Long-Term Follow-up of a Phase 2 Nonrandomized Comparative Trial with Radical CystectomyEuropean Urology, 2009
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychological Bulletin, 1968